SAS Output

23-FEB-2019 6:11

OPEN STUDIES IRB REPORT

The REPORT Procedure

Detailed and/or summarized report

Table 1

Disease
Site
Study Study Name Open Date Number of
Active
Institutions
Number of
Current
IRBs
 
BREAST S1207 Brst,Adj,Endocrine+/-Everolimus 03-SEP-13 440 205
  S1416 Brst, TNBC/BRCA, Cis+/- ABT-888 07-JUL-16 292 150
  S1418 Breast, Adj, TNBC, MK-3475 (Pembrolizumab) 15-NOV-16 478 210
  S1706 Breast, Inflammatory, RT +/- Olaparib 12-SEP-18 0 56
  A011106 Breast, Neoadj, ALTERNATE study 15-FEB-14 278 114
  A011401 Breast, adj, Stage II/III HER2-, weight loss 29-AUG-16 486 246
  A011502 Brst, Adj, Nodal+&HER2-, Aspirin vs. Placebo 08-DEC-16 0 260
  A221405 Breast, ET interruption, Pregnancy Outcomes 15-OCT-15 0 55
  B51 Breast, Regional Nodal XRT 22-AUG-13 316 170
  B55 Brst, Adj Olaparib for BRCA,TNBC 03-JUL-14 439 185
  E1Z11 Brst,Genetic Predictors of AIMSS 10-MAY-13 17 11
  EA1151 Brst, Tomosynthesis Mammographic Screening 06-JUL-17 0 72
  NRGBR002 Brst, OMBC, II-III, SoC +/- SBRT and/or SA 24-DEC-14 0 141
  NRGBR003 Brst,Adj,TNBC,AC -> WP +/- Carbo 22-JAN-15 337 173
  NRGBR005 Br, Stg II&IIIA, Post NAdj Chemo Br Conserv 13-APR-17 0 78
 
CCD S1415CD TrACER CSF Standing Order Intervention for FN 01-SEP-16 2 6
  S1703 Met Breast, STM-monitoring v Usual Care 16-JUL-18 0 65
  A011104 Preoperative Breast MRI 21-FEB-14 76 17
  A191402C PROS, Testing Decision Aids for Minority Men 14-JUL-17 0 10
  ACCL16N1 Guideline Consistent Treatment AYA ALL 18-DEC-17 0 10
  EAQ162CD CCD, Financial Burden, Colon & Rectal Cancer 17-MAY-18 0 67
 
ERLYTX S1609 Rare Tumor, Comb Nivo/Ipi 13-JAN-17 318 157
  A071401 Prog Meningiomas,SMO/AKT/NF2 Inhib 06-AUG-15 227 91
  ARST1321 NonRhabdo STS,Pazopanib (PAZNTIS) 16-MAY-14 261 119
  EAY131 MATCH 12-AUG-15 384 207
 
GI S1613 mCRC, Adv/Met, TP vs CETIRI 09-OCT-17 0 142
  S1815 Biliary, Met/LocAdv, GC+CPT±Nab-paclitaxel 03-DEC-18 0 44
  A021501 Adeno Panc,Borderline Resect,Chemo vs ChemoRT 01-DEC-16 0 15
  A021502 Colon, Stg III, Chemo +/- Atezol, ATOMIC 12-SEP-17 0 157
  EA2142 GI NEC, Adv G3, EP vs TMZ + CAP 06-NOV-15 170 69
  EA2161 PANC, Adv Rapalog Resistant PNETs, MLN0128 01-FEB-17 0 11
  EA2165 Anal, Stg II-III, Nivolumab after CMT 13-APR-18 0 33
  NRGGI004 Colorectal, Stg IV, dMMR Immuno-Therapy 07-NOV-17 0 117
 
GU S1500 pRCC,Adv, Sunitinib vs MET inhib 05-APR-16 211 88
  S1602 Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG 07-FEB-17 182 70
  S1605 Blad, BCG-Unresponsive NMIBC, Atezolizumab 07-FEB-17 195 92
  S1802 Pros, Stg IV, SST +/- Surg/RT to Primary Tum 17-SEP-18 0 80
  A031102 GCT, Recur, Std Chemo(TIP) vs HD Chemo(TI-CE) 01-JUL-15 55 34
  A031501 Bladder, MIBC/Loc Adv, Adjv Pembro vs Obs 21-SEP-17 0 123
  A031701 Bladder, ddGC for MIBC with DDR Tumor Alt 01-AUG-18 0 3
  EA8143 RCC, HR, Surg +/- Nivolumab (PROSPER) 02-FEB-17 0 146
  EA8153 Pros, ADT + Abira +/- Cabazitaxel (CHAARTED2) 08-FEB-18 0 24
  NRGGU002 Pros, RT + ADT After RP +/- Adj Docetaxel 30-DEC-16 0 108
  R0924 Pros, NADT+WPRT vs. NADT+P&SV RT 07-JUL-11 0 122
 
LEUK S1712 CML, chronic phase, TKI +/- Ruxolitinib 20-JUL-18 0 53
  A041501 B-Cell ALL, Frontline Tx +/- Intuzumab Ozo 01-JUN-17 0 52
  E1910 BCR-ABL-neg, B ALL, Blinatumomab 23-DEC-13 174 86
  E2906 AML, Age 60+, Clo vs Dauno+Cy 24-FEB-11 155 70
  NHLBIMDS LEUK, National MDS Study 05-APR-16 212 81
 
LUNG S1400F Non-Match: MEDI4736 + Tremelimumab 02-OCT-17 0 206
  S1619 Meso,Stg I-III, Nadj chemo/Atezmb->Atezmb+SOC 03-NOV-17 0 24
  S1701 Thymic Adv, Carbo/Pac/Ram vs. Carbo/Pac 09-AUG-18 0 21
  S1900A LOH and/or BRCA: Rucaparib 28-JAN-19 0 39
  A081105 ALCHEMIST1, EGFR mut, Erlotinib 02-JAN-14 0 253
  A151216 ALCHEMIST0 - screening 06-FEB-14 493 253
  C30610 SCLC, Thoracic RT 21-MAR-08 166 86
  E4512 ALCHEMIST2, ALK mut, Crizotinib 18-AUG-14 380 218
  EA5142 ALCHEMIST3, Non-match, Nivolumab 16-MAY-16 468 250
  LUNGMAP NSCLC, Adv, Master 28-JAN-19 0 91
  NRGCC003 SCLC, PCI or HA-PCI 07-DEC-15 257 125
 
LYMPH S1608 FL, TGR-1202/Lenalidomide/CHOP or Benda +Ob 10-AUG-17 0 106
  A051301 ABC DLBCL, Auto HCT and Ibrutinib/Placebo 15-JUL-16 166 68
  EA4151 Lymph, AHCT +/-Ritux, MRD Neg 29-AUG-17 0 60
 
MELAN S1320 Adv, BRAF mut, Inter v Contin 22-JUL-14 233 98
  S1512 Melan, Adv, Desmoplastic, MK-3475 (pembro) 20-OCT-16 89 41
  S1607 MELAN, Adv, T-VEC, MK-3475 02-OCT-17 0 19
  S1616 MELAN, Adv, Ipilimumab ± Nivolumab 17-JUL-17 0 109
  S1801 Melan, Adv, Adj vs Neoadj Pembrolizumab 06-DEC-18 0 52
  EA6134 Adv, BRAF mut, D+T/Ipi+Niv vs Ipi+Niv/D+T 15-DEC-15 364 144
  EA6141 Melan, Avd, Nivolumab+Ipi ± Sargmostim 01-MAR-16 225 94
 
MMYEL S1702 AL Amyloidosis, Relapsed, Isatuximab 08-MAR-18 0 70
  E1A11 MM, frontline, BLD vs CLD 22-NOV-13 300 125
 
OTHER A091401 Sarc, 18-JUN-15 183 72
  EA3132 HN SCC, Stg III-IV , Adj RT +/- Cisp 29-MAR-16 0 68
  EAF151 Brain, GBM, Bev, Blood Volume 14-APR-17 0 34
  EAQ152 Communication & education in tumor profiling 26-SEP-16 183 78
  G0263 Cerv, Stg I/IIA, adjv RT vs chemoRT 12-APR-10 0 63
  N0577 BRN, Glio,Tem vs Tem+RT vsRT+PVC 22-SEP-09 172 77
  NRGBN001 HN, novel vs. std chemoradiation + chemo 28-AUG-15 0 77
  NRGGY005 OVAR, Cedir vs Olaparib vs C+O vs Std of Care 06-FEB-16 334 144
  NRGGY009 Ovar, PLD/Atexo vs PLD/Atezo/Bev vs PLD/Bev 12-MAY-17 0 127
  NRGHN001 Nasopharyngeal , Indiviual Tx EBV 21-APR-14 210 75
  R0724 Cervical, Chem+RT +/- Adj. Chemo 15-JAN-14 195 82
  R1216 HN, Adv,Cis vs Dtx vs Dtx+Cetux 18-MAR-13 202 84
 
PREV S0820 PACES: ColrecStg0-3 Blind DFMO/Sulindac 01-MAR-13 50 18
  A211102 Breast, Atypia via RPFNA, Metformin v Placebo 01-FEB-15 0 3
 
SURV S1501 Surv, Breast Stg IV, Card Tox w/ Carvedilol 15-SEP-17 0 111
  E1Q11 EROS: Reproductive Health in Cancer Survivors 30-SEP-15 0 38
  EA9131 Leuk, Strategy to decrease early APL deaths 16-AUG-17 0 26
 
SXQOL A221101 Glioma, Nuvigil/Placebo Fatigue 03-JUN-13 53 15
  A221504 NSCL, Advanced, placebo vs naloxegol 13-OCT-17 0 5
  A221505 Brst, Hypofractionated Post Mast Rad 01-FEB-18 0 91